Moderna Inc.
plans to double the measure of ongoing experimental testing, the Covid-19 vaccine in children six months old to less than 12 years.
According to updated details on the Klinistrials.gov clinical trial record site, this study will now register around 13,275 participants, almost double the previous target of 6,975 participants.
In July, Modernama said he was discussing with the instructions of US food & medicine to expand their studies with the aim of registering a larger safety database, which increased the possibility of detecting rare events.
The company vaccine, which received emergency authorization for people aged 18 years and over in the United States in December, is currently under the FDA reviews for use in adolescents.
Rival Shot from Pfizer Inc.
and German partner BLANTECH was permitted for ages 12 to 15 years earlier this year.
Moderna doubled the size of a pediatric study Covid-19 vaccine
